Glenmark Life Sciences Sustainability Profile
Glenmark Life Sciences, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions, including North America, Europe, and Asia. Founded in 2013, the company has rapidly established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations, particularly in the therapeutic areas of cardiology, diabetes, and central nervous system disorders. With a commitment to quality and innovation, Glenmark Life Sciences offers a diverse portfolio of products that cater to both generic and branded markets. The company is recognised for its robust research and development capabilities, which have led to significant milestones in API production. As a subsidiary of Glenmark Pharmaceuticals, it has garnered a strong market position, contributing to the global healthcare landscape with its high-quality, cost-effective solutions.
DitchCarbon Score
How does Glenmark Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Life Sciences's score of 21 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glenmark Life Sciences's reported carbon emissions
In 2024, Glenmark Life Sciences reported total carbon emissions of approximately 667,131,590 kg CO2e for Scope 1 and 59,703,280 kg CO2e for Scope 2. This data reflects their global operations, with emissions from Scope 1 indicating direct emissions from owned or controlled sources, while Scope 2 represents indirect emissions from the generation of purchased electricity, steam, heating, and cooling. For the previous year, 2023, Glenmark's emissions were approximately 12,798,000 kg CO2e for Scope 1 and 50,407,400 kg CO2e for Scope 2. This shows a significant increase in Scope 1 emissions, which may warrant further investigation into operational changes or increased production activities. Glenmark Life Sciences does not currently disclose any Scope 3 emissions, which encompass all other indirect emissions that occur in a company's value chain. Additionally, there are no specific reduction targets or climate pledges outlined in their recent reports, indicating a potential area for future commitment. It is important to note that Glenmark Life Sciences is a current subsidiary of Alivus Life Sciences Limited, and emissions data may be cascaded from this parent organization. The emissions data and performance metrics are sourced from Alivus Life Sciences Limited, reflecting the broader corporate family’s environmental impact. Overall, while Glenmark Life Sciences has made strides in reporting their emissions, the absence of reduction targets suggests an opportunity for enhanced climate action and commitment to sustainability in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 26,879,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 49,900,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Glenmark Life Sciences's Industry?
How Carbon Intensive is Glenmark Life Sciences's Location?
Glenmark Life Sciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Glenmark Life Sciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
